54.1-3450 - Schedule III.
§ 54.1-3450. Schedule III.
The controlled substances listed in this section are included in Schedule III:
1. Unless specifically exempted or listed in another schedule, any material,compound, mixture, or preparation which contains any quantity of thefollowing substances having a depressant effect on the central nervous system:
Any substance which contains any quantity of a derivative of barbituric acid,or any salt of a derivative of barbituric acid, except those substances whichare specifically listed in other schedules;
Any compound, mixture or preparation containing amobarbital, secobarbital, orpentobarbital or any salt of amobarbital, secobarbital, or pentobarbital andone or more other active medicinal ingredients which are not listed inSchedules II through V;
Any suppository dosage form containing amobarbital, secobarbital, orpentobarbital or any salt of amobarbital, secobarbital, or pentobarbital andapproved by the Food and Drug Administration for marketing only as asuppository;
Chlorhexadol;
Any drug product containing gamma hydroxybutyric acid, including its salts,isomers, and salts of isomers, for which an application is approved undersection 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355);
Embutramide;
Ketamine, its salts, isomers, and salts of isomers (some other names: [+-]-2-[2-chlorophenyl]-2-[methylamino]-cyclohexanone);
Lysergic acid;
Lysergic acid amide;
Methyprylon;
Sulfondiethylmethane;
Sulfonethylmethane;
Sulfonmethane; and
Tiletamine - zolazepam combination product or any salt thereof.
2. Nalorphine.
3. Unless specifically excepted or unless listed in another schedule:
a. Any material, compound, mixture, or preparation containing any of thefollowing narcotic drugs or their salts thereof:
Buprenorphine.
b. Any material, compound, mixture, or preparation containing limitedquantities of any of the following narcotic drugs, or any salts thereof:
Not more than 1.8 grams of codeine, or any of its salts, per 100 millilitersor not more than 90 milligrams per dosage unit, with an equal or greaterquantity of an isoquinoline alkaloid of opium;
Not more than 1.8 grams of codeine, or any of its salts, per 100 millilitersor not more than 90 milligrams per dosage unit, with one or more active,nonnarcotic ingredients in recognized therapeutic amounts;
Not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of itssalts, per 100 milliliters or not more than 15 milligrams per dosage unit,with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
Not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of itssalts, per 100 milliliters or not more than 15 milligrams per dosage unit,with one or more active, nonnarcotic ingredients in recognized therapeuticamounts;
Not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100milliliters or not more than 90 milligrams per dosage unit, with one or moreactive, nonnarcotic ingredients in recognized therapeutic amounts;
Not more than 300 milligrams of ethylmorphine, or any of its salts, per 100milliliters or not more than 15 milligrams per dosage unit, with one or moreingredients in recognized therapeutic amounts;
Not more than 500 milligrams of opium per 100 milliliters or per 100 grams,or not more than 25 milligrams per dosage unit, with one or more active,nonnarcotic ingredients in recognized therapeutic amounts;
Not more than 50 milligrams of morphine, or any of its salts, per 100milliliters or per 100 grams with one or more active, nonnarcotic ingredientsin recognized therapeutic amounts.
4. Unless specifically excepted or unless listed in another schedule, anymaterial, compound, mixture, or preparation which contains any quantity ofthe following substances having a stimulant effect on the central nervoussystem, including its salts, isomers (whether optical, position, orgeometric), and salts of such isomers whenever the existence of such salts,isomers, and salts of isomers is possible within the specific chemicaldesignation:
Benzphetamine;
Chlorphentermine;
Clortermine;
Phendimetrazine.
5. The Board may except by regulation any compound, mixture, or preparationcontaining any stimulation or depressant substance listed in subsection Afrom the application of all or any part of this chapter if the compound,mixture, or preparation contains one or more active medicinal ingredients nothaving a stimulant or depressant effect on the central nervous system, and ifthe admixtures are included therein in combinations, quantity, proportion, orconcentration that vitiate the potential for abuse of the substances whichhave a stimulant or depressant effect on the central nervous system.
6. Unless specifically excepted or unless listed in another schedule, anymaterial, compound, mixture, or preparation containing any quantity of thefollowing substances, including its salts, isomers, and salts of isomerswhenever the existence of such salts of isomers is possible within thespecific chemical designation:
Anabolic steroids, including, but not limited to:
3beta,17-dihydroxy-5a-androstane;
3alpha,17beta-dihydroxy-5a-androstane;
5alpha-androstan-3,17-dione;
1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene);
1-androstenediol (3alpha,17beta-dihydroxy-5alpha-androst-1-ene);
4-androstenediol (3beta,17beta-dihydroxy-androst-4-ene);
5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene);
1-androstenedione ([5alpha]-androst-1-en-3,17-dione);
4-androstenedione (androst-4-en-3,17-dione);
5-androstenedione (androst-5-en-3,17-dione);
Bolasterone (7alpha,17alpha-dimenthyl-17beta-hydroxyandrost-4-en-3-one);
Boldenone (Dehydrotestosterone) (17beta-hydroxyandrost-1,4,-diene-3-one);
Boldione (androsta-1, 4-diene-3, 17-dione);
Calusterone (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
Clostebol (4-Chlorotestosterone) (Chlorotestosterone)(4-chloro-17beta-hydroxyandrost-4-en-3-one);
Dehydrochloromethyltestosterone(4-chloro-17beta-hydroxy-17alpha-methyl-androst-1,4-dien-3-one);
Delta1-dihydrotestosterone (1-testosterone)(17beta-hydroxy-5alpha-androst-1-en-3-one);
Desoxymethyltestosterone (madol)(17alpha-methyl-5alpha-androst-2-en-17beta-ol);
Dromostanolone (Drostanolone)(17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);
Ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene);
Fluoxymesterone(9-fluoro-17alpha-methyl-11beta,17beta-dihydroxyandrost-4-en-3-one);
Formyldienolone (Formebolone) (2-formyl-17alpha-methyl-11alpha,
17beta-dihydroxyandrost-1,4-dien-3-one);
Furazabol (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);
13-beta-ethyl-17alpha-hydroxygon-4-en-3-one;
4-hydroxytestosterone (4,17beta-dihydroxy-androst-4-en-3-one);
4-hydroxy-19-nortestosterone (4,17beta-dihydroxy-estr-4-en-3-one);
Mestanolone (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);
Mesterolone (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);
Methandriol (methylandrostenediol)(17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene);
Methandrostenolone (Methandienone) (Dehydromethyltestosterone)
(17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one);
Methenolone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);
17alpha-methyl-3beta,17beta-dihydroxy-5a-androstane;
17alpha-methyl-3alpha,17beta-dihydroxy-5a-androstane;
17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene);
17alpha-methyl-4-hydroxynandrolone(17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);
Methyldienolone (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);
Methyltrienolone (17alpha-methyl-17beta-hydroxyestra-4,9-11-trien-3-one);
17-Methyltestosterone (Methyltestosterone)(17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);
Mibolerone (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);
17alpha-methyl-delta1-dihydrotestosterone(17beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one)(17-alpha-methyl-1-testosterone);
Nandrolone (19-Nortestosterone) (17beta-hydroxyestr-4-en-3-one);
19-nor-4, 9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
19-nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene);
19-nor-4-androstenediol (3alpha,17beta-dihydroxyestr-4-ene);
19-nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene);
19-nor-5-androstenediol (3alpha,17beta-dihydroxyestr-5-ene);
19-nor-4-androstenedione (estr-4-en-3,17-dione);
19-nor-5-androstenedione (estr-5-en-3,17-dione);
Norbolethone (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one);
Norclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one);
Norethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);
Normethandrolone (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);
Oxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);
Oxymesterone (Oxymestrone)(17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);
Oxymetholone (Anasterone) (17alpha-methyl-2-hydroxymethylene-
17beta-hydroxy-[5alpha]-androstan-3-one);
Stanolone (4-Dihydrotestosterone) (Dihydrotestosterone)(17beta-hydroxy-androstan-3-one);
Stanozolol (Androstanazole)(17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-pyrazole);
Stenbolone (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);
Testolactone (1-Dehydrotestololactone)(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
Testosterone (17beta-hydroxandrost-4-en-3-one);
Tetrahydrogestrinone(13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);
Trenbolone (Trienbolone) (Trienolone)(17beta-hydroxyestr-4,9,11-trien-3-one); and
Any salt, ester, or ether of a drug or substance described or listed in thisparagraph. However, such term does not include an anabolic steroid which isexpressly intended for administration through implants to cattle or othernonhuman species and which has been approved by the United States Secretaryof Health and Human Services for such administration. If any personprescribes, dispenses, or distributes any such steroid for human use, suchperson shall be considered to have prescribed, dispensed, or distributed ananabolic steroid within the meaning of this subsection.
7. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatincapsule in a drug product approved by the U.S. Food and Drug Administration.
(1972, c. 798, § 54-524.84:8; 1976, c. 614; 1977, c. 302; 1979, c. 387; 1982,c. 505; 1988, cc. 283, 765; 1992, c. 737; 2000, cc. 135, 348; 2003, c. 640;2005, c. 119; 2006, c. 346; 2007, c. 14; 2010, c. 423.)